ATE233785T1 - Onkoprotein protein kinase - Google Patents

Onkoprotein protein kinase

Info

Publication number
ATE233785T1
ATE233785T1 AT94922622T AT94922622T ATE233785T1 AT E233785 T1 ATE233785 T1 AT E233785T1 AT 94922622 T AT94922622 T AT 94922622T AT 94922622 T AT94922622 T AT 94922622T AT E233785 T1 ATE233785 T1 AT E233785T1
Authority
AT
Austria
Prior art keywords
jnk
protein kinase
jun
activation domain
terminal activation
Prior art date
Application number
AT94922622T
Other languages
English (en)
Inventor
Michael Karin
Masahiko Hibi
Anning Lin
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE233785(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/094,533 external-priority patent/US5534426A/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE233785T1 publication Critical patent/ATE233785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
AT94922622T 1993-07-19 1994-07-18 Onkoprotein protein kinase ATE233785T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/094,533 US5534426A (en) 1993-07-19 1993-07-19 Oncoprotein protein kinase
US08/220,602 US6514745B1 (en) 1993-07-19 1994-03-25 Oncoprotein protein kinase
PCT/US1994/008120 WO1995003324A1 (en) 1993-07-19 1994-07-18 Oncoprotein protein kinase

Publications (1)

Publication Number Publication Date
ATE233785T1 true ATE233785T1 (de) 2003-03-15

Family

ID=26788998

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94922622T ATE233785T1 (de) 1993-07-19 1994-07-18 Onkoprotein protein kinase

Country Status (11)

Country Link
US (7) US6514745B1 (de)
EP (2) EP0728143B1 (de)
JP (3) JP2986548B2 (de)
AT (1) ATE233785T1 (de)
AU (2) AU700137B2 (de)
CA (2) CA2167302A1 (de)
DE (1) DE69432223T2 (de)
DK (1) DK0728143T3 (de)
ES (1) ES2191032T3 (de)
PT (1) PT728143E (de)
WO (2) WO1995003323A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US6846644B2 (en) * 1993-07-19 2005-01-25 The Regents Of The University Of California Oncoprotein protein kinase
US6001584A (en) 1993-07-19 1999-12-14 The Regents Of The University Of California Oncoprotein protein kinase
US5925557A (en) * 1994-09-29 1999-07-20 The Regents Of The University Of California DNA encoding mitogen activated protein kinase, FRK
US6132978A (en) * 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
EP1557467B1 (de) * 1996-08-16 2008-05-21 Genencor International, Inc. Expressionssystem, abgeleitet von der Lipase-Regulationskaskade von Pseudomonas alcaligenes.
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
JP2001518881A (ja) 1997-03-28 2001-10-16 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 乳癌治療剤としての有糸分裂活性化プロテインキナーゼのアンチセンスオリゴヌクレオチド
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
EP1820854B1 (de) * 1997-10-03 2010-07-28 University of Massachusetts JNK3-Modulatoren und Verwendungsverfahren dafür
WO1999041371A1 (en) * 1998-02-13 1999-08-19 Genetrace Systems, Inc. Use of ribozymes for functionating genes
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
EP0984070A1 (de) * 1998-08-31 2000-03-08 Boehringer Ingelheim International GmbH Verfahren zur Auffindung von Verbindungen für die Behandlung von Krankheiten die assoziert sind mit C-Jun vermittelte Apoptosis
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (de) * 1999-01-13 2011-12-28 Bayer HealthCare LLC GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
WO2000043524A1 (fr) * 1999-01-20 2000-07-27 Aventis Pharma S.A. Polypeptides derives de jnk3
FR2788531B1 (fr) * 1999-01-20 2003-01-31 Aventis Pharma Sa Nouveaux polypeptides derives de la proteine jnk3 humaine, leurs variants, les sequences nucleotidiques correspondantes, et leurs utilisations
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7232897B2 (en) * 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
MXPA03010706A (es) * 2001-05-24 2004-05-27 Cephalon Inc Nuevo polipeptido de quinasa (7) (mlk7) de linaje mezclado polinucleotidos que codifican al mismo y metodos para su uso.
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
AU2003294668A1 (en) * 2002-09-06 2004-04-08 Institut Curie Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (de) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
US20050020391A1 (en) * 2003-07-17 2005-01-27 Pinnacle Sports Equipment Co., Inc. Bamboo bat and method of manufacture
EP1663978B1 (de) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP2418219B1 (de) 2003-10-17 2018-06-27 InterK Peptide Therapeutics Limited Verfahren und wirkstoffe zur behandlung von krebs
JP5080241B2 (ja) * 2004-04-08 2012-11-21 メルク セローノ ソシエテ アノニム Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物
WO2009003211A1 (en) * 2007-06-29 2009-01-08 Newsouth Innovations Pty Limited Treatment of rheumatoid arthritis
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
EP4000595A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden
EP4000596A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109481A1 (en) * 1992-10-29 1994-04-30 Lea Eisenbach Anti-metastatic vaccine

Also Published As

Publication number Publication date
WO1995003324A1 (en) 1995-02-02
US6514745B1 (en) 2003-02-04
WO1995003323A1 (en) 1995-02-02
AU685484B2 (en) 1998-01-22
CA2167302A1 (en) 1995-02-02
US5804399A (en) 1998-09-08
US5994513A (en) 1999-11-30
US6193965B1 (en) 2001-02-27
DK0728143T3 (da) 2003-07-07
AU7338094A (en) 1995-02-20
DE69432223T2 (de) 2003-08-21
US5837244A (en) 1998-11-17
AU700137B2 (en) 1998-12-24
CA2166981C (en) 2000-11-07
ES2191032T3 (es) 2003-09-01
US5605808A (en) 1997-02-25
EP0726908A1 (de) 1996-08-21
JP2000023681A (ja) 2000-01-25
PT728143E (pt) 2003-06-30
EP0728143A4 (de) 1999-04-21
JPH09507384A (ja) 1997-07-29
JPH09500535A (ja) 1997-01-21
EP0728143B1 (de) 2003-03-05
JP2986548B2 (ja) 1999-12-06
JP2925740B2 (ja) 1999-07-28
EP0726908A4 (de) 1999-04-07
JP3745558B2 (ja) 2006-02-15
EP0728143A1 (de) 1996-08-28
AU7366894A (en) 1995-02-20
DE69432223D1 (de) 2003-04-10
US5593884A (en) 1997-01-14

Similar Documents

Publication Publication Date Title
DE69432223D1 (de) Onkoprotein protein kinase
DE69434663D1 (de) Nukleotid-sequenzen zur kontrolle der exprimierung von dns-sequenzen in einem zellulärem wirt
HUT77431A (hu) Fonálféregből kivont szerinproteáz-inhibitorok és véralvadásgátló proteinek
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
DE69730315D1 (de) Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
DE69825066D1 (de) Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
EP0624348A3 (de) Bipolare elektrochirurgische Instrumente.
EP0597844A4 (de) Ziel-spezifische, zytotoxische, rekombinante exotoxine aus pseudomonas.
ATE236904T1 (de) Substituierte triazolo-pyridazin-derivate als liganden von gaba-rezeptoren
FR2819517B1 (fr) Composition comprenant un nitroxyde, un promoteur et eventuellement un initiateur de radicaux libres
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
EP1368467A4 (de) Putrescin-n-methyltransferasepromotor
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
ATE110074T1 (de) Quinolyloxazol-2-one, nützlich als proteinkinase- c-inhibitoren.
NO974035L (no) En ny vekstfaktor og en genetisk sekvens som koder for denne
ATE113982T1 (de) Verzweigungsenzym und dessen verwendung.
ES2058479T3 (es) Compuestos peptidicos.
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DE69635446D1 (de) Pflanzenpromoter und dessen verwendung zur genexpression
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
DE69432120D1 (de) Mit chemotherapeutische zusammensetzungenassoziierten genetischen suppressor-elementen
DK0506923T3 (da) Et collagenbindende protein samt fremstilling deraf
ATE380245T1 (de) Gen von alteromonas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0728143

Country of ref document: EP

RZN Patent revoked